RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Rapport Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$28.60+1.03 (+3.74%)
Close on Oct 19, 2026
- Market cap
- $1.36B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
51M of 48M shares
Institutional holders
161
29 new, 12 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 67 sales
Net sold $46.68M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Third Rock Ventures GP V, L.P. | 7,135,233 | 19.50% | 13G (passive) | Dec 31, 2024 |
| Trv Gp V, LLC | 6,280,525 | 13.10% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson | 5,486,468 | 15.00% | 13G (passive) amendment | Nov 12, 2024 |
| S) Kristina Burow | 3,728,738 | 10.20% | 13G (passive) | Sep 30, 2024 |
| Bihua Chen | 2,957,521 | 6.19% | 13G (passive) amendment | Mar 31, 2026 |
| Capital International Investors | 2,921,958 | 6.10% | 13G (passive) amendment | Jun 30, 2026 |
| Cormorant Asset Management, LP | 2,657,521 | 5.56% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 2,397,549 | 5.03% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RAPP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 7,172,894 | 14.95% | $298.89M | +3,955 | 0.01% |
| Trv Gp V, LLC | 6,280,525 | 13.09% | $261.71M | −854,708 | 52.53% |
| ARCH Venture Management, LLC | 3,728,738 | 7.77% | $155.38M | – | 14.12% |
| Capital International Investors | 2,921,958 | 6.09% | $121.76M | −176,015 | 0.03% |
| Goldman Sachs Group Inc | 2,910,449 | 6.07% | $121.28M | −31,802 | 0.01% |
| BlackRock, Inc. | 2,699,786 | 5.63% | $112.50M | +193,831 | 0.00% |
| Cormorant Asset Management, LP | 2,657,521 | 5.54% | $110.74M | −300,000 | 5.67% |
| Sofinnova Investments, Inc. | 1,904,408 | 3.97% | $79.36M | – | 4.10% |
| Johnson & Johnson | 1,784,517 | 3.72% | $74.36M | – | 9.31% |
| Polar Capital Holdings Plc | 1,608,514 | 3.35% | $67.03M | −33,947 | 0.16% |
| Baker Bros. Advisors LP | 1,547,090 | 3.22% | $64.47M | – | 0.32% |
| Vanguard Capital Management LLC | 1,346,512 | 2.81% | $56.11M | +21,430 | 0.00% |
| Trv Gp Vi, LLC | 969,218 | 2.02% | $40.39M | – | 17.39% |
| State Street Corp | 818,712 | 1.71% | $34.12M | +59,160 | 0.00% |
| Geode Capital Management, LLC | 793,453 | 1.65% | $33.07M | +71,831 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 787,446 | 1.64% | $32.81K | −79,010 | 0.00% |
| Perceptive Advisors LLC | 773,342 | 1.61% | $32.23M | +99,419 | 0.48% |
| Vestal Point Capital, LP | 730,000 | 1.52% | $30.42M | −706,229 | 0.71% |
| Alliancebernstein L.P. | 693,384 | 1.45% | $21.70M | −34,459 | 0.01% |
| UBS Asset Management Americas Inc | 644,082 | 1.34% | $26.84M | −274,784 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 161 | 51M | 100.0% | 29 / 57 | 46 / 12 | 2M | 3M |
| Q1 2026 | 147 | 52M | 100.0% | 30 / 52 | 35 / 24 | 5M | 2M |
| Q4 2025 | 144 | 51M | 100.0% | 40 / 51 | 30 / 20 | 5M | 3M |
| Q3 2025 | 124 | 49M | 100.0% | 51 / 38 | 19 / 9 | 13M | 3M |
| Q2 2025 | 82 | 38M | 80.2% | 15 / 28 | 19 / 9 | 2M | 2M |
| Q1 2025 | 77 | 38M | 79.4% | 17 / 35 | 9 / 9 | 2M | 1M |
| Q4 2024 | 70 | 37M | 76.2% | 20 / 18 | 15 / 5 | 9M | 1M |
| Q3 2024 | 55 | 28M | 59.3% | 30 / 11 | 7 / 10 | 4M | 1M |
| Q2 2024 | 35 | 26M | 53.3% | 35 / 0 | 0 / 0 | 26M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RAPP | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 3,113,161 | 6.49% | $129.73M | 0.14% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,251,968 | 4.69% | $88.95M | 0.09% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 986,730 | 2.06% | $41.12M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 798,325 | 1.66% | $33.27M | 0.04% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 687,115 | 1.43% | $27.14M | 0.10% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 592,106 | 1.23% | $23.39M | 0.10% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 571,905 | 1.19% | $23.83M | 0.20% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 428,273 | 0.89% | $16.92M | 0.32% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 335,415 | 0.70% | $13.75M | 0.04% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 328,598 | 0.68% | $13.69M | 0.01% | Jun 30, 2026 |
| AB Small Cap Growth Portfolio | 301,476 | 0.63% | $12.56M | 0.40% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 278,547 | 0.58% | $11.61M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 264,229 | 0.55% | $11.01M | 0.07% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 229,745 | 0.48% | $9.57M | 0.09% | Jun 30, 2026 |
| iShares Biotechnology ETF | 200,630 | 0.42% | $8.36M | 0.09% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Abraham Ceesay | Chief Executive Officer, Director | 559,268 | 1.17% | Sep 24, 2026 |
| Krishnaswamy Yeleswaram | Chief Development Officer | 212,063 | 0.44% | Aug 26, 2026 |
| Cheryl Gault | Chief Operating Officer | 154,222 | 0.32% | Jul 1, 2026 |
| David Bredt | Chief Scientific Officer | 393,075 | 0.82% | Feb 19, 2026 |
| Jeffrey Sevigny | Chief Medical Officer | – | – | Feb 4, 2026 |
| Troy A. Ignelzi | Chief Financial Officer | 10,000 | 0.02% | Feb 4, 2026 |
| Ramiro Sanchez | Director | – | – | Jun 10, 2026 |
| Wendy B. Young | Director | 9,500 | 0.02% | Jun 10, 2026 |
| Steven M. Paul | Director | 519,308 | 1.08% | Jun 10, 2026 |
| Paul M. Silva | Director | – | – | Jun 10, 2026 |
| James Healy | Director | 1,988,308 | 4.14% | Jun 10, 2026 |
| Reid M. Huber | Director | 20,400 | 0.04% | Jun 10, 2026 |
| Robert J. Perez | Director | – | – | Jun 10, 2026 |
| John Maraganore | Director | – | – | Jun 10, 2026 |
| Third Rock Ventures VI, L.P. | 10% owner | 7,401,933 | 15.43% | May 28, 2026 |
| Trv Gp Vi, Llc | 10% owner | – | – | May 28, 2026 |
| Third Rock Ventures GP V, LP | 10% owner | – | – | May 28, 2026 |
| Third Rock Ventures V, L.P. | 10% owner | 7,249,743 | 15.11% | May 28, 2026 |
| Third Rock Ventures GP VI, L.P. | 10% owner | – | – | May 28, 2026 |
| Trv Gp V, Llc | 10% owner | – | – | May 28, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Abraham Ceesay Chief Executive Officer, Director | Sep 23, 2026 | Sale(10b5-1 plan) | −215 | $39.86 | $8.57K | 456,810 |
| Abraham Ceesay Chief Executive Officer, Director | Sep 23, 2026 | Sale(10b5-1 plan) | −1,952 | $39.05 | $76.23K | 457,025 |
| Abraham Ceesay Chief Executive Officer, Director | Sep 23, 2026 | Sale(10b5-1 plan) | −43 | $41.05 | $1.77K | 456,767 |
| Abraham Ceesay Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −1,069 | $46.01 | $49.18K | 458,977 |
| Abraham Ceesay Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −7,141 | $45.56 | $325.34K | 460,046 |
| Abraham Ceesay Chief Executive Officer, Director | Aug 25, 2026 | Sale(10b5-1 plan) | −18,921 | $49.57 | $937.91K | 467,187 |
| Krishnaswamy Yeleswaram Chief Development Officer | Aug 25, 2026 | Sale(10b5-1 plan) | −20,799 | $50.31 | $1.05M | 212,063 |
| Krishnaswamy Yeleswaram Chief Development Officer | Aug 25, 2026 | Sale(10b5-1 plan) | −16,201 | $51.06 | $827.22K | 195,862 |
| Krishnaswamy Yeleswaram Chief Development Officer | Aug 24, 2026 | Sale(10b5-1 plan) | −13,160 | $50.00 | $658.00K | 232,862 |
| Krishnaswamy Yeleswaram Chief Development Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −404 | $49.90 | $20.16K | 246,022 |
| Abraham Ceesay Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −5,794 | $48.62 | $281.70K | 486,108 |
| Abraham Ceesay Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −19,500 | $48.04 | $936.78K | 491,902 |
| Abraham Ceesay Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −3,664 | $46.90 | $171.84K | 511,402 |
| Abraham Ceesay Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −8,370 | $46.75 | $391.30K | 515,066 |
| Abraham Ceesay Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −14,171 | $45.97 | $651.44K | 523,436 |
| Abraham Ceesay Chief Executive Officer, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −7 | $42.74 | $299 | 537,607 |
| Abraham Ceesay Chief Executive Officer, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −2,203 | $42.11 | $92.77K | 537,614 |
| Abraham Ceesay Chief Executive Officer, Director | Jul 14, 2026 | Sale(10b5-1 plan) | −5,481 | $39.72 | $217.71K | 542,546 |
| Abraham Ceesay Chief Executive Officer, Director | Jul 14, 2026 | Sale(10b5-1 plan) | −2,729 | $40.57 | $110.72K | 539,817 |
| Cheryl Gault Chief Operating Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −3,792 | $41.39 | $156.95K | 154,222 |
| Cheryl Gault Chief Operating Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −1,900 | $40.09 | $76.17K | 158,014 |
| Cheryl Gault Chief Operating Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −3,308 | $42.17 | $139.50K | 150,914 |
| Cheryl Gault Chief Operating Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −1,000 | $43.15 | $43.15K | 149,914 |
| Abraham Ceesay Chief Executive Officer, Director | Jun 29, 2026 | Sale(10b5-1 plan) | −7,344 | $39.77 | $292.07K | 548,903 |
| Abraham Ceesay Chief Executive Officer, Director | Jun 29, 2026 | Sale(10b5-1 plan) | −876 | $40.34 | $35.34K | 548,027 |
| Third Rock Ventures V, L.P. 10% owner | May 26, 2026 | Sale(10b5-1 plan) | −18,572 | $40.05 | $743.81K | 6,280,525 |
| Third Rock Ventures V, L.P. 10% owner | May 11, 2026 | Sale(10b5-1 plan) | −133,618 | $40.24 | $5.38M | 6,299,097 |
| Third Rock Ventures VI, L.P. 10% owner | May 8, 2026 | Sale(10b5-1 plan) | −5,018 | $40.31 | $202.28K | 6,432,715 |
| Third Rock Ventures VI, L.P. 10% owner | May 7, 2026 | Sale(10b5-1 plan) | −271,495 | $40.12 | $10.89M | 6,437,733 |
| Third Rock Ventures VI, L.P. 10% owner | Apr 17, 2026 | Sale(10b5-1 plan) | −426,005 | $40.32 | $17.18M | 6,709,228 |
| Krishnaswamy Yeleswaram Chief Development Officer | Apr 17, 2026 | Sale(10b5-1 plan) | −20,225 | $39.99 | $808.80K | 246,426 |
| Krishnaswamy Yeleswaram Chief Development Officer | Apr 14, 2026 | Sale(10b5-1 plan) | −10,200 | $35.08 | $357.82K | 266,651 |
| Krishnaswamy Yeleswaram Chief Development Officer | Apr 13, 2026 | Sale(10b5-1 plan) | −9,165 | $34.97 | $320.50K | 276,851 |
| Krishnaswamy Yeleswaram Chief Development Officer | Apr 10, 2026 | Sale(10b5-1 plan) | −500 | $34.98 | $17.49K | 286,016 |
| Krishnaswamy Yeleswaram Chief Development Officer | Apr 8, 2026 | Sale(10b5-1 plan) | −360 | $34.90 | $12.56K | 286,516 |
| Cheryl Gault Chief Operating Officer | Mar 30, 2026 | Sale(10b5-1 plan) | −2,839 | $28.55 | $81.05K | 159,914 |
| Cheryl Gault Chief Operating Officer | Mar 30, 2026 | Sale(10b5-1 plan) | −7,161 | $28.04 | $200.79K | 162,753 |
| Krishnaswamy Yeleswaram Chief Development Officer | Mar 25, 2026 | Sale(10b5-1 plan) | −10,115 | $29.99 | $303.35K | 286,876 |
| Cheryl Gault Chief Operating Officer | Mar 5, 2026 | Sale | −2,014 | $28.93 | $58.27K | 169,914 |
| David Bredt Chief Scientific Officer | Feb 19, 2026 | Option exercise | +6,000 | $1.80 | $10.80K | 393,075 |
| Abraham Ceesay Chief Executive Officer, Director | Feb 18, 2026 | Sale(10b5-1 plan) | −2,281 | $29.80 | $67.97K | 556,247 |
| Abraham Ceesay Chief Executive Officer, Director | Feb 18, 2026 | Sale(10b5-1 plan) | −2,983 | $29.04 | $86.63K | 22,829 |
| Abraham Ceesay Chief Executive Officer, Director | Feb 18, 2026 | Sale(10b5-1 plan) | −2,100 | $29.80 | $62.58K | 20,729 |
| Abraham Ceesay Chief Executive Officer, Director | Feb 18, 2026 | Sale(10b5-1 plan) | −3,552 | $29.05 | $103.19K | 558,528 |
| David Bredt Chief Scientific Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −900 | $28.02 | $25.22K | 394,675 |
| David Bredt Chief Scientific Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −5,400 | $28.95 | $156.33K | 389,275 |
| David Bredt Chief Scientific Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −2,200 | $29.59 | $65.10K | 387,075 |
| Abraham Ceesay Chief Executive Officer, Director | Jan 20, 2026 | Sale(10b5-1 plan) | −5,833 | $26.12 | $152.36K | 562,080 |
| Abraham Ceesay Chief Executive Officer, Director | Jan 20, 2026 | Sale(10b5-1 plan) | −5,083 | $26.11 | $132.72K | 25,812 |
| David Bredt Chief Scientific Officer | Jan 15, 2026 | Sale(10b5-1 plan) | −200 | $27.40 | $5.48K | 395,575 |
| David Bredt Chief Scientific Officer | Jan 15, 2026 | Sale(10b5-1 plan) | −8,300 | $26.83 | $222.69K | 395,775 |
| Krishnaswamy Yeleswaram Chief Development Officer | Dec 31, 2025 | Sale | −2,840 | $30.05 | $85.34K | 296,991 |
| Krishnaswamy Yeleswaram Chief Development Officer | Dec 31, 2025 | Award | +9,000 | – | – | 299,831 |
| David Bredt Chief Scientific Officer | Dec 31, 2025 | Award | −18,000 | – | – | 410,642 |
| David Bredt Chief Scientific Officer | Dec 31, 2025 | Sale | −6,567 | $30.05 | $197.34K | 404,075 |
| Abraham Ceesay Chief Executive Officer, Director | Dec 17, 2025 | Sale(10b5-1 plan) | −2,147 | $28.84 | $61.92K | 33,831 |
| Abraham Ceesay Chief Executive Officer, Director | Dec 17, 2025 | Sale(10b5-1 plan) | −600 | $31.04 | $18.62K | 567,913 |
| Abraham Ceesay Chief Executive Officer, Director | Dec 17, 2025 | Sale(10b5-1 plan) | −2,441 | $28.84 | $70.40K | 571,305 |
| Abraham Ceesay Chief Executive Officer, Director | Dec 17, 2025 | Sale(10b5-1 plan) | −2,421 | $30.04 | $72.73K | 31,410 |
| Abraham Ceesay Chief Executive Officer, Director | Dec 17, 2025 | Sale(10b5-1 plan) | −515 | $31.04 | $15.99K | 30,895 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| N. Ceesay Abraham Officer | Oct 6, 2026 | 39,470 | $1.23M | Oct 6, 2026 | Acquired as compensation -- Performance Awards |
| Gault Cheryl Officer | Sep 30, 2026 | 10,000 | $330.20K | Sep 30, 2026 | Founders Shares |
| Yeleswaram Krishnaswamy Officer | Aug 25, 2026 | 37,000 | $1.83M | Aug 25, 2026 | Founders Shares |
| Yeleswaram Krishnaswamy Officer | Aug 24, 2026 | 11,472 | $553.41K | Aug 24, 2026 | Founders Shares |
| Yeleswaram Krishnaswamy Officer | Aug 19, 2026 | 2,092 | $102.53K | Aug 19, 2026 | Founders Shares |
| Gault Cheryl Officer | Jun 30, 2026 | 10,000 | $403.90K | Jun 30, 2026 | Founders Shares |
| N. Ceesay Abraham Officer | Jun 29, 2026 | 99,480 | $4.02M | Jun 29, 2026 | Acquired as compensation -- Performance Awards |
| Third Rock Ventures V, L.P. 10% Stockholder | May 27, 2026 | 18,572 | $742.88K | May 26, 2026 | Original Issuance |
| Third Rock Ventures V, L.P. 10% Stockholder | May 11, 2026 | 133,618 | $5.38M | May 11, 2026 | Original Issuance |
| Third Rock Ventures V, L.P. 10% Stockholder | May 8, 2026 | 5,018 | $202.25K | May 8, 2026 | Original Issuance |
| Third Rock Ventures V, L.P. 10% Stockholder | May 7, 2026 | 271,495 | $10.89M | May 7, 2026 | Original Issuance |
| Yeleswaram Krishnaswamy Officer | Apr 17, 2026 | 20,225 | $799.70K | Apr 17, 2026 | Founders Shares |
| Third Rock Ventures V, L.P. 10% Stockholder | Apr 17, 2026 | 426,005 | $17.18M | Apr 17, 2026 | Original Issuance |
| Yeleswaram Krishnaswamy Officer | Apr 13, 2026 | 19,365 | $661.70K | Apr 13, 2026 | Founders Shares |
| Yeleswaram Krishnaswamy Officer | Apr 10, 2026 | 500 | $17.11K | Apr 10, 2026 | Founders Shares |